Company Filing History:
Years Active: 2000
Title: Antonette Preisinger Allen: Innovator in Cancer Genetics
Introduction
Antonette Preisinger Allen is a notable inventor based in Severn, MD (US). She has made significant contributions to the field of cancer genetics, particularly through her research on the BRCA1 and BRCA2 genes. With a total of 2 patents, her work has the potential to impact cancer susceptibility testing and treatment.
Latest Patents
Antonette's latest patents focus on identifying mutations in the BRCA1 and BRCA2 genes. The first patent details new mutations found in the BRCA1 gene, specifically at nucleotide numbers 421-2, 815, 903, 926, 1506, 2034, 2428, 3888, 3904, 4164, 4643, 5053, 5150, 5210, or 5396+40. This patent discloses a process for identifying sequence variations in a BRCA1 polynucleotide sequence, utilizing allele-specific sequence-based assays for accurate mutation detection. The second patent addresses new mutations in the BRCA2 gene, located at nucleotide numbers 2192, 3772, 5193, 5374, 6495, or 6909. Similar to her work on BRCA1, this patent outlines a method for identifying sequence variations in BRCA2, enhancing the efficiency and accuracy of mutation detection in test samples.
Career Highlights
Antonette Preisinger Allen is currently associated with Oncormed, Inc., where she continues her research in cancer genetics. Her innovative work has positioned her as a key figure in the development of genetic testing methodologies that can lead to better cancer risk assessment and management.
Collaborations
Some of her notable coworkers include Sheri J Olson and Tammy Lawrence. Their collaborative efforts contribute to the advancement of research in the field of oncology and genetics.
Conclusion
Antonette Preisinger Allen's contributions to cancer genetics through her patents on BRCA1 and BRCA2 mutations highlight her role as an innovator in the field. Her work not only enhances our understanding of cancer susceptibility but also paves the way for improved diagnostic techniques.